ATE357245T1 - Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs - Google Patents

Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs

Info

Publication number
ATE357245T1
ATE357245T1 AT04380188T AT04380188T ATE357245T1 AT E357245 T1 ATE357245 T1 AT E357245T1 AT 04380188 T AT04380188 T AT 04380188T AT 04380188 T AT04380188 T AT 04380188T AT E357245 T1 ATE357245 T1 AT E357245T1
Authority
AT
Austria
Prior art keywords
fviii
vwf
liquid composition
human origin
stable liquid
Prior art date
Application number
AT04380188T
Other languages
English (en)
Inventor
Gamon Salvador Grancha
Nieto Juan Ignacio Jorquera
Debart Pere Ristol
Riera Marta Massot
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Application granted granted Critical
Publication of ATE357245T1 publication Critical patent/ATE357245T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04380188T 2003-10-03 2004-09-24 Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs ATE357245T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302298A ES2229931B1 (es) 2003-10-03 2003-10-03 Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Publications (1)

Publication Number Publication Date
ATE357245T1 true ATE357245T1 (de) 2007-04-15

Family

ID=34307115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04380188T ATE357245T1 (de) 2003-10-03 2004-09-24 Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs

Country Status (12)

Country Link
US (1) US20050074866A1 (de)
EP (1) EP1522312B1 (de)
JP (1) JP4388875B2 (de)
AR (1) AR047756A1 (de)
AT (1) ATE357245T1 (de)
CA (1) CA2481593C (de)
DE (1) DE602004005392T2 (de)
ES (2) ES2229931B1 (de)
MX (1) MXPA04009246A (de)
PL (1) PL1522312T3 (de)
PT (1) PT1522312E (de)
UY (1) UY28531A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2349314B1 (de) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP6029674B2 (ja) * 2011-10-18 2016-11-24 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
CN105705516B (zh) * 2013-11-08 2019-11-01 杰特有限公司 浓缩von Willebrand因子或其络合物的方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2022218962A1 (en) 2021-04-13 2022-10-20 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
MX2024001882A (es) * 2021-08-11 2024-02-29 Grifols Worldwide Operations Ltd Metodo para producir factor viii / factor de von willebrand derivado de plasma humano y composicion obtenida.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
JPS59116228A (ja) * 1982-12-24 1984-07-05 Green Cross Corp:The 血液凝固第８因子脂肪小体製剤の製法
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii

Also Published As

Publication number Publication date
MXPA04009246A (es) 2005-04-06
CA2481593C (en) 2009-10-20
PT1522312E (pt) 2007-06-19
UY28531A1 (es) 2005-03-31
EP1522312B1 (de) 2007-03-21
CA2481593A1 (en) 2005-04-03
EP1522312A1 (de) 2005-04-13
ES2280924T3 (es) 2007-09-16
AR047756A1 (es) 2006-02-22
US20050074866A1 (en) 2005-04-07
DE602004005392T2 (de) 2007-12-06
ES2229931B1 (es) 2006-01-16
PL1522312T3 (pl) 2007-08-31
HK1075406A1 (en) 2005-12-16
DE602004005392D1 (de) 2007-05-03
JP2005112855A (ja) 2005-04-28
ES2229931A1 (es) 2005-04-16
JP4388875B2 (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
ATE357245T1 (de) Biologisch stabile flüssige zusammensetzung von fviii, vwf oder fviii/vwf-komplex menschlichen ursprungs
EP1617854A4 (de) Biologisch wirksame native biomatrix-zusammensetzung
DK1440148T3 (da) Keratinocytter anvendelige som biologisk aktive substanser i behandling af sår
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
EP1506786A4 (de) Medizinische, ghrelin enthaltende zusammensetzungen
DE60309383D1 (de) Silberhaltige Dentalzusammensetzung
DE602005012267D1 (de) N von geräten
ATE521334T1 (de) Schweisshemmende oder desodorierende zusammensetzung
DE60323947D1 (de) Co-perlchen von dha und rosmarin
ATE380813T1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
DE50311735D1 (de) Das tissue engineering von knochen
EP1434645A4 (de) Entfernung von metabolischen komponenten aus blut
DE60331183D1 (de) Kontrollierte dosierung von chlordioxid oder anderersystemen
DE602005027308D1 (de) Stabile salze von olanzapin
DK1572229T3 (da) Stabilt terapeutisk fibrinogen
DE602004014485D1 (de) Zusammensetzung und anwendungen von galectin-antagonisten
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60317639D1 (de) Zusammensetzungen enthaltend n-acyl-phosphatidyl-ethanolamin und/oder mischungen von n-acyl-ethanolaminen mit phosphatidinsäuren oder lysophosphatidinsäuren
EP1512405A4 (de) Zusammensetzung zur linderung von chloasma und zusammensetzung zur linderung von stumpfem aussehen
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
EP1500693A4 (de) Schmiermittelzusammensetzung
ATE316101T1 (de) Thrombinspaltbare faktor-x-analoga
EP1740120A4 (de) Langzeitformulierungen von naltrexon und anwendungsverfahren
IS7166A (is) Notkun annellataðra pýrrólsambanda í meðhöndlun áliðabrjósks- eða neðanbrjósksbeinahrörnun
EP1467673A4 (de) Irrigationslösung und verwendungsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1522312

Country of ref document: EP